MIA research wins Cancer Institute of NSW 'Wildfire Highly Cited Publication'
7 December 2021
Join us in celebrating Professor Georgina Long AO, winner of the 2021 NSW Premier's Award for Wildfire Highly Cited Publication.
The 2021 NSW Premier's Wildfire Highly Cited Publication Award is presented to an individual or research team for a highly cited publication that has a significant impact on the cancer field.
This year, the publication is: Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study (Lancet Oncol. 2018 May;19(5):672–to681).
The report was authored by Professor Georgina Long AO together with MIA's Professor Richard Scolyer AO, Associate Professor Alexander Menzies, Maria Gonzalez and Jarem Edwards.
Originally published in 2018, it has now been cited an incredible 427 times around the world – showing its vital role in improving outcomes for people with advanced melanoma.
“This trial single-handedly changed practice overnight,” Professor Long explains.
The MIA team’s research aimed to establish the efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with metastatic melanoma that had spread to the brain (active melanoma brain metastases).
“Our ABC trial (Anti-PD1 Brain Collaboration) was conducted across Australia, and it showed that combination immunotherapy significantly improved the long-term durable control of melanoma in patients with brain metastases,” Professor Long says.
“It is the only randomised trial demonstrating that combination was so effective, and has much higher response and survival than single agent anti-PD1 immunotherapy.”
This is a significant conclusion, as this treatment may lead to better outcomes for people with advanced melanoma, as well as other cancers.
Professor Long leads an extensive clinical trials team and laboratory at MIA, with a focus on targeted therapies and immuno-oncology in melanoma and is a previous recipient of the Cancer Institute NSW Outstanding Cancer Researcher Award.
“Our advances and successes in melanoma research are a true team effort,” Professor Long reflects. “This is only possible through the collaborative work of the many talented and dedicated researchers who are part of the MIA team in conjunction with our world class trials centre.”
New research from MIA has been published that forms the basis of the updated international guidelines for staging melanoma.
Professor William McCarthy AM has been awarded the Tom Reeve Award for Outstanding Contributions to Cancer Care.
Leading researchers from MIA have been acknowledged with three prestigious awards for excellence in melanoma research.
New research shows that patients who are more likely to respond to immunotherapy treatment have a greater diversity in their gut bacteria.
2018 will be bigger than ever, and a little bit different.
MIA's epidemiologist explains her new research on how country of residence should be considered when identifying melanoma risk.
Congratulations to our Conjoint Medical Directors, Professor Georgina Long and Professor Richard Scolyer, who have today been announced as Fellows of the Australian Academy of Health and Medical Sciences.
New research shows potentially deadly UV damage can appear decades earlier than you think.
Early lymph node check is saving lives in melanoma patients
We are pleased to announce that A/Prof Anne Cust is the new President of the Australasian Epidemiological Association.
More than $3.5 million in competitive funding grants have been awarded to MIA's researchers.
The ESMO conference provided a platform for announcing a number of key melanoma research findings - including practice-changing research from MIA.
Australian researchers have successfully trialled a combination of new treatments to prevent melanoma from spreading to distant organs.
A new treatment that combines an antibody with a cancer-killing virus improves outcomes for patients with advanced melanoma, an international clinical trial has shown.
It feels like groundhog day - another reality TV show, another batch of blatantly sunburnt contestants.
Wouldn’t it be great if your doctor could know if you would respond to treatment before you even had it?
In our latest research update we showcase research in survival estimates, uncover biomarkers, and reveal practice-changing research in surgery and medical oncology.
Senior Clinical Trial Coordinators, like Sarah Lane, support melanoma patients throughout the clinical trial process.
Melanomas are often hard to differentiate from moles. But new technology is helping to improve accuracy of diagnosis.